Biotime-Nasdaq's best kept secret? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret?

BTIM 0.0001000

0.0%

Nov 5 1:26 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Roof who wrote (830)	4/15/1998 1:49:00 AM
From: Stephen How	Read Replies (1) of 1432

Reference #3 in the Phase III Trial Poster Presentation (16th Annual Symposium Clinical Update in Anesthesiology, San Juan, Puerto Rico; siliconinvestor.com is invalid. The reference reads: "3. Bick RL. Evaluation of a new hydroxyethyl starch preparation (Hextend) on selected coagulation parameters. Clin Appl Thrombosis/Hemostasis 1995; 1:215-29." I couldn't find the reference either on Medline, or at the local UC medical library. There are quite a few related papers by Bick RL, but I couldn't find the journal "Clinical Applications of Thrombosis ..." in the medical library. Neither was there any paper with a similar title by Dr. Bick. Here's the Medline search I used: ncbi.nlm.nih.gov (Or, go to ncbi.nlm.nih.gov and enter Bick [AU] AND coagulation or Bick [AU] AND hydroxyethyl or just Hextend ) I'll try to contact the authors, and Dr. Bick at the University of Texas Southwestern Medical Center and Dallas Thrombosis Hemostasis Clinical Center. Steve btim.dyn.ml.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next